

Journal of Visualized Experiments

Measuring the Effects of Bacteria and Chemicals on the Intestinal Permeability of *Caenorhabditis elegans* --Manuscript Draft--

Article Type:	Methods Article - JoVE Produced Video
Manuscript Number:	JoVE60419R2
Full Title:	Measuring the Effects of Bacteria and Chemicals on the Intestinal Permeability of <i>Caenorhabditis elegans</i>
Section/Category:	JoVE Biology
Keywords:	3,3'-Diindolylmethane, <i>Caenorhabditis elegans</i> , FITC-dextran, gut health, high-throughput image analysis, intestinal permeability, <i>Pseudomonas aeruginosa</i>
Corresponding Author:	Kyungsu Kang, Ph.D. Korea Institute of Science and Technology Gangneung, Gangwon-do KOREA, REPUBLIC OF
Corresponding Author's Institution:	Korea Institute of Science and Technology
Corresponding Author E-Mail:	kskang@kist.re.kr
Order of Authors:	Tram Anh Ngoc Le Baskar Selvaraj Jae Wook Lee Kyungsu Kang, Ph.D.
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Gangneung, South Korea

TITLE:

Measuring the Effects of Bacteria and Chemicals on the Intestinal Permeability of *Caenorhabditis elegans*

AUTHORS:

Tram Anh Ngoc Le¹, Baskar Selvaraj^{1,2}, Jae Wook Lee^{1,2}, Kyungsu Kang¹,

¹Gangneung Institute of Natural Products, Korea Institute of Science and Technology, Republic of Korea

²Division of Bio-Medical Science & Technology, Korea University of Science and Technology (UST), Republic of Korea

Email addresses of coauthors:

Tram Anh Ngoc Le (Intramanh@kist.re.kr)

Baskar Selvaraj (baskars@kist.re.kr)

Jae Wook Lee (jwlee5@kist.re.kr)

Corresponding author:

Kyungsu Kang (kskang@kist.re.kr)

KEYWORDS:

3,3'-diindolylmethane, *Caenorhabditis elegans*, FITC-dextran, gut health, high-throughput image analysis, intestinal permeability, *Pseudomonas aeruginosa*.

SUMMARY:

This protocol describes how to measure intestinal permeability of *Caenorhabditis elegans*. This method is helpful for basic biological research on intestinal health related to the interaction between intestinal bacteria and their host and for screening to identify probiotic and chemical agents to cure leaky gut syndrome and inflammatory bowel diseases.

ABSTRACT:

In living organisms, intestinal hyperpermeability is a serious symptom that leads to many inflammatory bowel diseases (IBDs). *Caenorhabditis elegans* is a nonmammalian animal model that is widely used as an assay system due to its short lifespan, transparency, cost-effectiveness, and lack of animal ethics issues. In this study, a method was developed to investigate the effects of different bacteria and 3,3'-diindolylmethane (DIM) on the intestinal permeability of *C. elegans* with a high-throughput image analysis system. The worms were infected with different gut bacteria or cotreated with DIM for 48 h and fed with fluorescein isothiocyanate (FITC)-dextran overnight. Then, the intestinal permeability was examined by comparing the fluorescence images and the fluorescence intensity inside the worm bodies. This method may also have the potential to identify probiotic and pathogenic intestinal bacteria that affect intestinal permeability in the animal model and is effective for examining the effects of harmful or health-promoting chemicals on intestinal permeability and intestinal health. However, this protocol also has some considerable limitations at the genetic level, especially for determining which genes are altered to control illness, because this method is mostly used for

phenotypic determination. In addition, this method is limited to determining exactly which pathogenic substrates cause inflammation or increase the permeability of the worms' intestines during infection. Therefore, further in-depth studies, including investigation of the molecular genetic mechanism using mutant bacteria and nematodes as well as chemical component analysis of bacteria, are required to fully evaluate the function of bacteria and chemicals in determining intestinal permeability.

INTRODUCTION:

Intestinal permeability is considered as one of the main barriers related to the intestinal microbiota and mucosal immunity and is likely to be affected by several factors, such as gut microbiota modifications, epithelial impairment, or mucus layer alterations¹. Recent papers have reported effective protocols to measure the intestinal permeability of cultured human intestinal cells by analyzing the fluorescence flux rates across the intestinal cell layer², but fewer research papers present a suitable procedure for measuring the gut permeability in nematodes, particularly in *C. elegans*, by using FITC-dextran staining.

There are two representative protocols for measuring the gut permeability in *C. elegans* using Nile red³ and eriochlorine disodium (or the Smurf assay)^{4,5}. In this protocol, we used FITC-dextran (average molecular weight 10,000), which has a much higher molecular weight than Nile red (MW = 318.37) and eriochlorine disodium (MW = 792.85). FITC-dextran is more similar than Nile red or eriochlorine disodium dyes to actual macromolecular nutrients such as carbohydrates, which are absorbed through the intestinal layer. The intestinal permeability of *C. elegans* fed with eriochlorine disodium (blue Smurf dye) can be easily evaluated without fluorescence microscopy. However, in the Smurf assay, quantitative analysis of intestinal permeability is difficult due to the lack of standardization and should be evaluated manually^{4,5}. In the case of the Nile red assay, Nile red also stains lipid droplets in cells, which may interfere with the exact determination of gut permeability in *C. elegans*⁶. The present protocols enable rapid and precise quantitative analysis of intestinal permeability in *C. elegans* treated with various intestinal bacteria and chemicals while avoiding unspecific lipid staining.

C. elegans is a typical model in biological fields due to its affordable price, easy manipulation, limited animal ethics issues, and short lifespan, which is beneficial for rapid experimentation⁷. In particular, after the entire *C. elegans* genome was published, nearly 40% of genes in the *C. elegans* genome were found to be orthologous to genes that cause human diseases⁸. Moreover, the transparent body allows observation inside the organism, which is advantageous for researching cellular events and for fluorescence applications in cell biology, for example, stem cell staining with DAPI or immunohistochemistry⁹. *C. elegans* is often used as an experimental animal to study the interaction between the gut microbiota and the host; in addition, *C. elegans* is used to screen health-promoting probiotic bacteria¹⁰⁻¹² as well as dietary chemicals promoting intestinal health^{13,14}.

Pseudomonas aeruginosa and *Enterococcus faecalis* are well-known gut bacteria that negatively affect the gastrointestinal system, especially the colonic epithelial cells of the intestinal tract^{15,16}. Therefore, measuring the gut permeability triggered by these bacteria is necessary for

the screening and development of new drugs that can recover and reduce the damage caused by bacterial inflammation and infection. In this protocol, we tested the effects of these intestinal bacteria on the intestinal permeability of *C. elegans*.

We also report an optimized protocol for testing chemicals on the intestinal permeability of *C. elegans*. For this purpose, we used 3,3'-diindolylmethane (DIM) as a model chemical because DIM is a bioactive metabolite compound derived from indole-3-carbinol, which is present in *Brassica* food plants, and has been reported to have therapeutic effects on IBD in mice^{17,18}. In addition, we recently discovered that DIM improves intestinal permeability dysfunction in both cultured human intestinal cells as well as the model nematode *C. elegans*¹⁹.

In this study, we used three different experimental conditions. First, we measured the effects of the different bacteria, *P. aeruginosa* and *E. faecalis*, on intestinal permeability (**Figure 1**). Second, we measured the effects of live and heat-inactivated *P. aeruginosa* on intestinal permeability (**Figure 2**). Third, we measured the effects of DIM (a model chemical) on the intestinal permeability of *C. elegans* fed with *P. aeruginosa* (**Figure 3**).

The objective of this study was to develop optimized protocols that measure the intestinal permeability of *C. elegans*, which is changed by treatment with various intestinal bacteria as well as with chemicals.

PROTOCOL:

1. Preparation of *P. aeruginosa* PAO1 and *Escherichia coli* OP50 culture

1.1. Prepare 500 mL of sterilized Luria-Bertani (LB) medium (**Table 1**) and inoculate a single colony of *P. aeruginosa* into the medium. Incubate the culture for 14 to 15 h at 37 °C with a shaking speed of 150 rpm.

1.2. Equally distribute the bacterial culture into two 500-mL centrifuge tubes and centrifuge the tubes at 3,220 x g at 4 °C for 30 min.

1.3. Remove the supernatant until the volume is 50 mL (one-tenth of the initial volume) and resuspend the bacterial pellet.

1.4. Store the concentrated bacterial culture at 4 °C until use. The storage period of *P. aeruginosa* culture can be up to 1 month, but fresh culture is better for inducing intestinal damage.

NOTE: The protocol can be paused here. In addition to the whole live bacteria, the supernatant of the bacterial culture can be used to test the effects of the intestinal bacteria¹⁹.

1.5. To prepare *E. coli* OP50, culture *E. coli* OP50 in DYT medium (**Table 1**) and then apply similar steps to those described above but decrease the volume to one-sixth of the original

133 volume. For example, if the initial volume is 500 mL, after removing supernatant, the remaining
134 volume is approximately 83 mL.

135
136 NOTE: The protocol can be paused here.

137 138 **2. Preparation of *Enterococcus faecalis* KCTC 3206 culture**

139
140 2.1. Prepare 500 mL of sterilized brain heart infusion (BHI) broth (**Table 1**).

141
142 2.2. Inoculate one colony into 500 mL of BHI broth and incubate the culture for 14 – 15 h in a
143 shaking incubator at 37 °C and 150 rpm.

144
145 2.3. Equally distribute the bacterial culture into two 500-mL centrifuge tubes and centrifuge
146 the tubes at $3,220 \times g$ at 4 °C for 30 min.

147
148 2.4. Remove the supernatant until the volume is 50 mL (one-tenth of the initial volume) and
149 resuspend the pellet.

150
151 2.5. Store the concentrated bacterial culture at 4 °C until use. The fresh culture is better for
152 testing the effects on the intestinal permeability.

153
154 NOTE: The protocol can be paused here.

155 156 **3. Preparation of heat-inactivated *E. coli* OP50 and heat-inactivated *P. aeruginosa* PAO1** 157 **cultures**

158
159 3.1. Culture and harvest the bacteria as described above (steps 1.1-1.3).

160
161 3.2. Heat-inactivate the *E. coli* OP50 or *P. aeruginosa* PAO1 culture as described previously²⁰⁻
162 ²². For heat inactivation, incubate the resuspended bacteria at 65 °C (water bath) for 30 min.

163
164 3.3. Cool the concentrated bacterial culture to room temperature and store it at 4 °C until
165 use. The storage period can be up to 1 month.

166
167 NOTE: The protocol can be paused here.

168 169 **4. Preparation of nematode growth medium (NGM) plates for testing the effects of** 170 **different bacteria on the intestinal permeability of *C. elegans***

171
172 4.1. Place 1.25 g of peptone, 1.5 g of NaCl, 8.5 g of agar, a magnetic stirrer and 487.5 mL of
173 distilled water in a 500-mL glass bottle (**Table 1**).

174
175 4.2. Mix the mixture well, autoclave the mixture for 15 min at 121 °C and cool the mixture to
176 55 °C in a water bath for 30 min.

4.3. Remove the medium from the water bath, add the components (0.5 mL of 1 M CaCl₂, 0.5 mL of cholesterol, 0.5 mL of MgSO₄, 12.5 mL of KPO₄) (**Table 1**) to the NGM, and mix well.

NOTE: All the individual components must be autoclaved except for cholesterol (dissolved in absolute ethanol), and every experimental step must be carried out on a clean bench.

4.4. Distribute 20 mL of NGM to each 90 x 15 mm Petri dish and allow the agar to solidify on a clean bench at room temperature (approximately 20 °C). The NGM plates can be stored for up to one month at 4 °C.

NOTE: The protocol can be paused here. The NGM plates used for FITC-dextran staining were prepared by the same procedure (from steps 4.1-4.3). 10 mL of NGM was distributed to each 60 x 15 mm Petri dish and allowed to solidify on a clean bench at room temperature (approximately 20 °C).

4.5. Remove the bacterial culture from the 4 °C refrigerator and vortex the culture thoroughly before spreading the culture onto the NGM plates.

4.6. Add a total of 800 µL of the bacterial culture to each fresh NGM plate, and allow the plates to dry in a 20 °C incubator overnight.

NOTE: For the first experiment (**Figure 1**), two NGM plates with *E. coli* OP50, one NGM plate with *P. aeruginosa* PAO1, and one NGM plate with *E. faecalis* KCTC3206 were prepared. For the second experiment (**Figure 2**), two NGM plates with live *E. coli* OP50, one NGM plate with live *P. aeruginosa* PAO1, and one NGM plate with heat-inactivated *P. aeruginosa* PAO1 were prepared.

5. Preparation of NGM plates for testing the effects of a chemical (DIM) on the intestinal permeability of *C. elegans* fed with *P. aeruginosa*

5.1. Add 0.5 g of peptone, 0.6 g of NaCl, 195 mL of distilled water, a magnetic stirrer, and 6.8 g of agar to a 500-mL glass bottle (NGM agar).

5.2. Add 0.5 g of peptone, 0.6 g of NaCl, 195 mL of distilled water, and a magnetic stirrer without agar to another 500-mL glass bottle (NGM broth).

5.3. Autoclave the two bottles (from steps 5.1-5.2), one empty 100-mL glass bottle, and one empty 500-mL glass bottle for 15 min at 121 °C. Then, allow the medium containing bottles to cool to 55 °C in the water bath for 30 min. Keep the agar medium in the water bath and remove the bottle containing broth (from step 5.2) for the next step.

5.4. Add the additive chemicals to the NGM broth: 0.4 mL of 1 M CaCl₂, 0.4 mL of cholesterol in ethanol (mL), 0.4 mL of 1 M MgSO₄ and 10 mL of 1 M KPO₄ (all of these components must be

sterilized apart from the cholesterol in ethanol). Then, stir the mixture thoroughly with a magnetic stirrer at 55 °C.

5.5. Label the autoclaved empty 500-mL glass bottle with dimethyl sulfoxide (DMSO) and the autoclaved empty 100-mL glass bottle with DIM.

5.6. Transfer 50 mL of NGM broth into the DIM-labeled 100-mL bottle. Add 500 µL of 20 mM DIM stock into the bottle and mix well.

NOTE: DIM is dissolved in DMSO (20 mM DIM stock).

5.7. Quickly remove the NGM agar medium from the water bath, add 50 mL of the NGM agar medium into the DIM-labeled bottle and mix thoroughly.

5.8. Place a 20-mL aliquot of DIM-containing NGM medium into each 90 x 15 mm Petri dish. Approximately five DIM-containing NGM plates can be made from this step.

NOTE: The final concentration of DIM in each NGM plate will be 100 µM.

5.9. To prepare the DMSO-containing NGM plate, transfer 150 mL of NGM broth into the DMSO-labeled 500-mL bottle. Add 1.5 mL of DMSO to the bottle and mix well.

5.10. Add 150 mL of the NGM agar medium to the DMSO-labeled bottle and mix thoroughly.

5.11. Place a 20-mL aliquot of DMSO-containing NGM medium in each 90 x 15 mm Petri dish. Approximately fifteen DMSO-containing NGM plates can be made from this step.

NOTE: The final concentration of DMSO in each NGM plate will be 0.5%.

5.12. Solidify the plates at room temperature for at least 3 h and store them at 4 °C until use.

NOTE: The protocol can be paused here.

5.13. Remove the *E. coli* OP50 or *P. aeruginosa* PAO1 culture from the 4 °C refrigerator (from step 1.4) and vortex the culture properly before spreading onto the NGM plates.

5.14. Put 800 µL of the *E. coli* OP50 or *P. aeruginosa* PAO1 bacterial culture onto each fresh NGM agar plate and allow the plates to dry in a 20 °C incubator overnight.

NOTE: The protocol can be paused here. For the third experiment (**Figure 3**), two DMSO-containing NGM plates coated with live *E. coli* OP50, one DMSO-containing NGM plate coated with live *P. aeruginosa* PAO1, and one DIM-containing NGM plate coated with live *P. aeruginosa* PAO1 were prepared.

6. Preparation of age-synchronized *C. elegans*

6.1. Grow worms on a solid NGM plate and feed them with *E. coli* OP50 until the desired population is reached.

6.2. Synchronize the eggs by using either the timed egg laying method or the bleaching solution treatment as described previously^{20,23,24}.

7. Treatment of bacteria or DIM and FITC-dextran feeding

7.1. Incubate the age-synchronized eggs at 20 °C for 64 h on NGM plates supplemented with live *E. coli* OP50 as food.

7.2. Wash the age-synchronized L4 larva with S-buffer and transfer them (more than approximately 500 worms) to the treatment NGM plates containing different bacteria and chemicals (described in NOTE following step 4.6 and 5.14,). Incubate them at 20 °C for 48 h.

NOTE: The treatment time can range from 24 to 72 h, according to the bacteria and chemicals used. The therapeutic or preventive effect of DIM can also be evaluated by pretreating the worms with pathogens and then treating the worms with DIM (the therapeutic effect) or by pretreating the worms with DIM and then treating with pathogens (the preventive effect)¹⁹.

7.3. To prepare the FITC-dextran-supplemented plates, mix 2 mL of heat-inactivated *E. coli* OP50 with 4 mg of FITC-dextran. Then, divide 100 µL of the FITC-dextran and *E. coli* OP50 mixture into twenty fresh NGM agar plates (60 x 15 mm) and allow the plates to dry for 1 h on a clean bench.

NOTE: The final concentration of FITC-dextran in each NGM plate will be 20 µg/mL.

7.4. Prepare five *E. coli* OP50-containing NGM plates without FITC-dextran for the vehicle control treatment. For this purpose, divide 100 µL heat-inactivated *E. coli* OP50 to each fresh NGM agar plates (60 x 15 mm) and allow the plates to dry for 1 h on a clean bench.

NOTE: For each independent experiment, fifteen FITC-dextran-supplemented NGM plates and five NGM plates without FITC-dextran are required.

7.5. After 48 h of treatment (from step 7.2), wash the worms with S-buffer, transfer the worms to the FITC-dextran supplemented plates and the NGM plates without FITC-dextran, and incubate the plates overnight (14-15 h).

NOTE: For each treatment group, 5 replicates of FITC-dextran staining (or vehicle control feeding) are required.

7.6. Wash the worms with S-buffer and allow them to crawl in the fresh NGM agar plate for

1 h.

NOTE: For each independent experiment, a total of 20 fresh NGM plates are needed. In this step, you can use the NGM plate supplemented without or with *E. coli* OP50.

7.7. Add 50 μ L of 4% formaldehyde solution to each well of a black 96-well flat-bottom plate. Transfer approximately 50 worms from each NGM plate into each well for fluorescence measurements. After 1 to 2 min, thoroughly remove all the formaldehyde from each well and add 100 μ L of mounting medium to coat the wells.

NOTE: Formaldehyde solution (4%) is used to immobilize and fix the worms. For each treatment group, 5 wells (5 replicates) are used for image analysis.

8. Imaging *C. elegans* with the Operetta imaging system and determination of intestinal permeability by measuring the FITC-dextran fluorescence uptake

NOTE: Fluorescent stereomicroscopy can be used for image analysis instead of the Operetta system.

8.1. Capture fluorescence images and measure the fluorescence intensity using the Operetta High-Content Imaging System and analyze the images with Harmony software.

8.2. In the Harmony software, press the icon **Open lid** to open the lid and to put the plate into the machine.

8.3. Set up the parameters.

8.4. Click **Set up**, select the plate type (96-well corning flat-bottom) and add the channels (bright-field and EGFP channels).

8.5. Adjust the layout. Go to the **Layout selection**, and then select **Track** and adjust the parameters (first picture at 1 μ m, number of planes are 10, distance is 1 μ m).

8.6. Select one of the treatment wells and one capture field and press **Test** to check whether the pictures are satisfactory in the **Run experiment** section.

8.7. If the pictures are satisfactory, return to the **Set up** section and press the **Reset** icon at the end of the screen. Then, select all the target wells and a suitable number of capture fields.

8.8. Go to **Run experiment** again and enter the plate name, then press **Start** to begin processing.

8.9. To measure the intensity of the fluorescence, go to the image analysis section and input the image. Find the cell by choosing the EGFP channel and method B. Adjust the common

threshold to 0.5, area to $>200\ \mu\text{m}^2$, split factor to 3.0, individual threshold to 0.18 and contrast to more than 0.18. Then, calculate the intensity properties and choose the mean as the output. Press the **Apply** icon to save the setup.

8.10. Go to the **Evaluation** section to measure the intensity by obtaining a heatmap and data table. Set the **Readout parameter** to **Cells – Intensity Cell EGFP Mean – Mean per Well** and start the evaluation.

NOTE: The protocol can be paused here.

8.11. To extract the data from Operetta, click the **Setting** button and choose **Data management**.

8.12. Choose **Write archive**, and then open the browse and select the file.

8.13. To select the file, click the small **+** signal at the left corner, and then click **Measurement** and choose **Plate name**.

8.14. Select the file and click **OK**.

8.15. Select the path to save the file by clicking the **Browse** signal at the active path.

8.16. Click **Start** to save the data file.

NOTE: The protocol can be paused here.

9. Statistical analysis of the FITC-dextran fluorescence of *C. elegans*

9.1. Import the data and calculate the mean and standard deviation (SD) using a statistics software.

9.2. Analyze the significant difference with one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test.

REPRESENTATIVE RESULTS:

After incubation with *P. aeruginosa* PAO1, *C. elegans* showed a significant increase in FITC-dextran fluorescence in the worm body compared to the fluorescence shown after incubation with the other two bacterial strains (**Figure 1**). The fluorescence intensities of worms fed with *E. coli* OP50, *P. aeruginosa* PAO1, and *E. faecalis* KCTC3206 were 100.0 ± 6.6 , 369.7 ± 38.9 , and $105.6 \pm 10.6\%$, respectively. The data emphasize that *P. aeruginosa* caused more vital damage to the epithelial gut barrier, and therefore, the worms exhibited a dramatic increase in their intestinal permeability. Based on this result, FITC-dextran can easily penetrate through the intestinal layer, so *P. aeruginosa* was selected as a potential candidate pathogen for screening the effects of DIM. Although *E. faecalis* is a gut pathogen that can produce extracellular

superoxide and hydrogen peroxide, which damage colonic epithelial cell DNA¹⁵, in some cases, *E. faecalis* is also known as a potential probiotic bacteria due to its ability to produce bacteriocins against some pathogens^{25,26}. The functions of a probiotic include adherence to epithelial surfaces, persistence in the human gastrointestinal tract, immune stimulation and antagonistic activity against intestinal pathogens²⁶. Therefore, the gut permeability of worms incubated with *E. faecalis* remained unchanged compared with that of the vehicle control worms. This result shows that the amount of the infection can be studied by the increase in the fluorescence intensity, and *P. aeruginosa* causes more intestinal permeability than other strains.

Figure 2 shows the difference between live and heat-inactivated *P. aeruginosa* PAO1 based on the intensity of FITC-dextran fluorescence in the worm body. Both the fluorescence images and statistical data indicate that the pathogen could not trigger any toxicity to nematodes after heat inactivation. *P. aeruginosa* can produce exotoxin A – a potent extracellular cytotoxin that is lethal for many animals²⁷. Exotoxin A can be rapidly abolished by heating at 45 °C to 60 °C²⁸. Therefore, heat-inactivated *P. aeruginosa* was unable to damage the permeability of the worms' intestinal epithelia. The supernatant of *P. aeruginosa* PAO1 culture significantly damaged intestinal permeability, and therefore, the culture supernatant instead of whole *P. aeruginosa* cells can be used to induce intestinal permeability dysfunction¹⁹. The supernatant contains endotoxins, exotoxin A, and lipopolysaccharides²⁹, and these components are known to induce cell toxicity^{30,31}. Therefore, these components of the supernatant may affect the intestinal permeability, although we did not check the direct effect of exotoxins and lipopolysaccharides on the intestinal permeability in *C. elegans*.

DIM cotreatment for 48 h significantly decreased the FITC-dextran fluorescence intensity inside the guts of worms compared with the *P. aeruginosa* single treatment (**Figure 3C, D**). Statistical analysis by one-way ANOVA and Tukey's multiple comparison test showed that after treatment with DIM, the mean fluorescence intensity was significantly decreased in comparison with the fluorescence intensity of the *P. aeruginosa*-only treatment. The fluorescence intensities of the worms treated with *P. aeruginosa*-only and *P. aeruginosa* plus DIM were 486.3 ± 41.7 and $414.2 \pm 25.0\%$, respectively (**Figure 3E**). Based on this result, DIM can be considered a good natural product to cure intestinal permeability dysfunction caused by bacterial infections. This result indicated that DIM can attenuate cell inflammation in gut cells, which reduces the permeability of the intestine¹⁹. This result is similar to the results obtained in a mouse model, in which DIM showed a significant reduction in inflammation in the colon³².

FIGURE LEGENDS:

Figure 1: The effects of different bacteria on the intestinal permeability of *C. elegans*. Microscopy images of the worms including bright-field, FITC fluorescence (green channel), and merged images. Microscopy images of worms from (A) *E. coli* OP50 without FITC-dextran feeding, (B) *E. coli* with FITC-dextran feeding, (C) *P. aeruginosa* PAO1 with FITC-dextran feeding, and (D) *E. faecalis* KCTC3206 with FITC-dextran feeding (white scale bar = 1 mm and black scale bar = 200 μ m). Age-synchronized L4 larvae were incubated for 48 h in NGM plates seeded with *E. coli* (A, B), *P. aeruginosa* (C), and *E. faecalis* (D). Then, the worms were transferred to plates

containing FITC-dextran (B-D), except for the vehicle control (A). (E) The FITC fluorescence intensity of the different bacterial treatments. A higher percentage of FITC fluorescence indicated a higher gut permeability. Columns and error bars indicate the mean \pm SD. *** P < 0.001 for significant difference from the vehicle control. #### P < 0.001 for significant difference from the FITC-dextran-treated worms fed with *P. aeruginosa* PAO1 (ANOVA, n = 5). This graph is representative of two independent experiments.

Figure 2: The effects of live and heat-inactivated *P. aeruginosa* PAO1 on the intestinal permeability of *C. elegans*. Microscopy images of worms from (A) live *E. coli* OP50 without FITC-dextran feeding, (B) live *E. coli* with FITC-dextran feeding, (C) live *P. aeruginosa* PAO1 with FITC-dextran feeding, and (D) heat-inactivated *P. aeruginosa* with FITC-dextran feeding (white scale bar = 1 mm and black scale bar = 200 μ m). Age-synchronized L4 larvae were incubated for 48 h in NGM plates seeded with live *E. coli* (A, B), live *P. aeruginosa* (C), and heat-inactivated *P. aeruginosa* (D). Then, the worms were transferred to plates containing FITC-dextran (B-D), except for the vehicle control (A). (E) FITC fluorescence intensity comparing live and heat-inactivated *P. aeruginosa* PAO1. Columns and error bars indicate the mean \pm SD. *** P < 0.001 and ** P < 0.01 for significant difference from the vehicle control. #### P < 0.001 for significant difference from the FITC-dextran-treated worms fed with live *P. aeruginosa* PAO1 (ANOVA, n = 5). This graph is representative of two independent experiments.

Figure 3: The effect of DIM on the intestinal permeability of *C. elegans* fed *P. aeruginosa*. Microscopy images of worms from (A) *E. coli* OP50 without FITC-dextran feeding, (B) *E. coli* with FITC-dextran feeding, (C) *P. aeruginosa* PAO1 with FITC-dextran feeding, and (D) *P. aeruginosa* and DIM (100 μ M) cotreatment with FITC-dextran feeding (white scale bar = 1 mm and black scale bar = 200 μ m). Age-synchronized L4 larvae were incubated for 48 h in NGM plates seeded with live *E. coli* (A, B), live *P. aeruginosa* (C), live *P. aeruginosa* and DIM (D). Then, the worms were transferred to plates containing FITC-dextran (B-D), except for the vehicle control (A). (E) The FITC fluorescence intensity indicates that the gut permeability of *C. elegans* was affected by DIM. Columns and error bars indicate the mean \pm SD. *** P < 0.001 for significant difference from the vehicle control. #### P < 0.001 and ## P < 0.01 for significant difference from the FITC-dextran-treated worms fed with *P. aeruginosa* PAO1 (ANOVA, n = 5). This graph is representative of two independent experiments.

DISCUSSION:

By utilizing this new method for determining gut permeability in *C. elegans*, which combines automated fluorescence microscopy and quantitative image analysis, the differences caused by intestinal microorganisms or chemicals can be determined in vivo, specifically in the *C. elegans* intestine. This protocol is useful for gut permeability investigations and applicable to many tasks, such as reactive oxygen species (ROS) determination under stress conditions and morphological examinations, due to its convenience and easy manipulation. Moreover, this method can be used to determine the effects of therapeutic and preventive methods against multiple pathogens in *C. elegans*. In particular, it may be an efficient protocol to investigate the mechanisms of different bacterial strains, including both harmful and useful bacteria. Some pathogens and probiotic bacteria with similar structures exert different effects on the host^{33,34}.

This procedure can assist in evaluating which mechanism the bacteria are utilizing and where the targeted substrates can be secreted extracellularly or intracellularly. In addition, this method can also help to strengthen the hypothesis that heat treatment plays a vital role in pathogen inactivation.

However, there are also some difficulties during this procedure. First, the number of worms in each plate is important for statistically meaningful results and robust worm detection, so 70 – 90% confluency (at least 50 worms per well) is recommended. Accordingly, trial experiments should be performed to obtain suitable worms. Second, the plate properties are one of the important factors that affect the quality of images and intensity determination, particularly for the bottom material. In some advanced experiments, a glass bottom is the best option for the measurement of fluorescence due to its excellent optical quality. However, because of the high price, a polystyrene bottom is often used, although the quality is not as high as that of the glass bottom. Finally, the plate coating methods for *C. elegans* require optimization. In this experiment, fluorescent mounting medium was applied because it can preserve and enhance the labeling of tissue sections, but it is unable to fix the worms on the plate bottom properly.

This protocol has limitations; as *C. elegans* is a nematode, further experiments, such as evaluation in human intestinal cell monolayers and in mammals, should be performed. In this method, the phenotypic changes in *C. elegans* fed pathogenic bacteria and chemicals were determined. Therefore, the molecular and genetic mechanisms underlying the pathogenic or probiotic effects of intestinal bacteria as well as the therapeutic effects of chemicals should be further elucidated. Specific signaling pathways exerted by pathogenic bacterial infection and therapeutic effects of chemicals can be evaluated using both various mutant bacteria and mutant worms. In addition, further in-depth studies identifying the chemical components responsible for the pathogenic and probiotic effects of intestinal bacteria would be beneficial.

Here, we report an experimental protocol for measuring intestinal permeability in *C. elegans* treated with different bacteria and chemicals by using FITC-dextran feeding. We believe that these protocols will be helpful for basic biological research, such as studying the interaction between the intestinal microbiota and gut health, as well as for the development of probiotics and nutraceuticals for the prevention and treatment of intestinal health problems.

ACKNOWLEDGMENTS:

This study was supported by a Korea Institute of Science and Technology intramural research grant (2E29563).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES

- 1 Bischoff, S. C. *et al.* Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterology*. **14**(1), 189 (2014).

529 2 Peng, L., Li, Z. R., Green, R. S., Holzman, I. R. & Lin, J. Butyrate enhances the intestinal
530 barrier by facilitating tight junction assembly via activation of AMP-activated protein
531 kinase in Caco-2 cell monolayers. *The Journal of Nutrition*. **139**(9), 1619-1625 (2009).

532 3 Ren, M. *et al.* Developmental basis for intestinal barrier against the toxicity of graphene
533 oxide. *Particle Fibre Toxicology*. **15**(1), 26 (2018).

534 4 Kissoyan, K. A. B. *et al.* Natural *C. elegans* microbiota protects against infection via
535 production of a cyclic lipopeptide of the viscosin group. *Current Biology*. **29**(6), 1030-
536 1037 (2019).

537 5 Gelino, S. *et al.* Intestinal autophagy improves healthspan and longevity in *C. elegans*
538 during dietary restriction. *PLoS Genetics*. **12**(7), e1006135 (2016).

539 6 Escorcia, W., Ruter, D. L., Nhan, J. & Curran, S. P. Quantification of lipid abundance and
540 evaluation of lipid distribution in *Caenorhabditis elegans* by Nile red and oil red O
541 staining. *Journal of Visualized Experiments*. (133), e57352 (2018).

542 7 Johnson, T. E. Advantages and disadvantages of *Caenorhabditis elegans* for aging
543 research. *Experimental Gerontology*. **38**(11-12), 1329-1332 (2003).

544 8 Culetto, E. & Sattelle, D. B. A role for *Caenorhabditis elegans* in understanding the
545 function and interactions of human disease genes. *Human Molecular Genetics*. **9**(6),
546 869-877 (2000).

547 9 Hubbard, E. J. A. *Caenorhabditis elegans* germ line: A model for stem cell biology.
548 *Developmental Dynamics*. **236**(12), 3343-3357 (2007).

549 10 Park, M. R. *et al.* Probiotic *Lactobacillus fermentum* strain JDFM216 stimulates the
550 longevity and immune response of *Caenorhabditis elegans* through a nuclear hormone
551 receptor. *Scientific Reports*. **8**, 7441 (2018).

552 11 Kim, Y. & Mylonakis, E. *Caenorhabditis elegans* immune conditioning with the probiotic
553 bacterium *Lactobacillus acidophilus* strain NCFM enhances gram-positive immune
554 responses. *Infection and Immunity*. **80**(7), 2500-2508 (2012).

555 12 Nakagawa, H. *et al.* Effects and mechanisms of prolongevity induced by *Lactobacillus*
556 *gasseri* SBT2055 in *Caenorhabditis elegans*. *Aging Cell*. **15**, (2), 227-236 (2016).

557 13 Dinh, J. *et al.* Cranberry extract standardized for proanthocyanidins promotes the
558 immune response of *Caenorhabditis elegans* to *Vibrio cholerae* through the p38 MAPK
559 pathway and HSF-1. *PLoS One*. **9**(7), e103290 (2014).

560 14 Vayndorf, E. M., Lee, S. S. & Liu, R. H. Whole apple extracts increase lifespan, healthspan
561 and resistance to stress in *Caenorhabditis elegans*. *Journal of Functional Foods*. **5**(3),
562 1236-1243 (2013).

563 15 Huycke, M. M., Abrams, V. & Moore, D. R. *Enterococcus faecalis* produces extracellular
564 superoxide and hydrogen peroxide that damages colonic epithelial cell DNA.
565 *Carcinogenesis*. **23**(3), 529-536 (2002).

566 16 Laughlin, R. S. *et al.* The key role of *Pseudomonas aeruginosa* PA-I lectin on
567 experimental gut-derived sepsis. *Annals of Surgery*. **232**(1), 133-142 (2000).

568 17 Huang, Z. *et al.* 3,3'-Diindolylmethane decreases VCAM-1 expression and alleviates
569 experimental colitis via a BRCA1-dependent antioxidant pathway. *Free Radical Biology &*
570 *Medicine*. **50**(2), 228-236 (2011).

571 18 Jeon, E. J. *et al.* Effect of Oral Administration of 3,3'-Diindolylmethane on Dextran
572 Sodium Sulfate-Induced Acute Colitis in Mice. *Journal of Agricultural and Food*

573 *Chemistry*. **64**, 7702-7709 (2016).

574 19 Kim, J. Y. *et al.* 3,3'-Diindolylmethane improves intestinal permeability dysfunction in
575 cultured human intestinal cells and the model animal *Caenorhabditis elegans*. *Journal of*
576 *Agricultural and Food Chemistry*. **67**(33), 9277-9285 (2019).

577 20 Lee, S. Y. & Kang, K. Measuring the Effect of Chemicals on the Growth and Reproduction
578 of *Caenorhabditis elegans*. *Journal of Visualized Experiments*. (128), e56437 (2017).

579 21 Schmeisser, S. *et al.* Neuronal ROS signaling rather than AMPK/sirtuin-mediated energy
580 sensing links dietary restriction to lifespan extension. *Molecular Metabolism*. **2**(2), 92-
581 102 (2013).

582 22 Lee, S. Y., Kim, J. Y., Jung, Y. J. & Kang, K. Toxicological evaluation of the topoisomerase
583 inhibitor, etoposide, in the model animal *Caenorhabditis elegans* and 3T3-L1 normal
584 murine cells. *Environmental Toxicology*. **32**(6), 1836-1843 (2017).

585 23 Sutphin, G. L. & Kaeberlein, M. Measuring *Caenorhabditis elegans* life span on solid
586 media. *Journal of Visualized Experiments*. (27), e1152 (2009).

587 24 Porta-de-la-Riva, M., Fontrodona, L., Villanueva, A. & Ceron, J. Basic *Caenorhabditis*
588 *elegans* methods: synchronization and observation. *Journal of Visualized Experiments*.
589 (64), e4019 (2012).

590 25 Al Atya, A. K. *et al.* Probiotic potential of *Enterococcus faecalis* strains isolated from
591 meconium. *Frontiers in Microbiology*. **6**, 227 (2015).

592 26 Hanchi, H., Mottawea, W., Sebei, K. & Hammami, R. The Genus *Enterococcus*: Between
593 Probiotic Potential and Safety Concerns-An Update. *Frontiers in Microbiology*. **9**, 1791
594 (2018).

595 27 Pollack, M. The role of exotoxin A in *Pseudomonas* disease and immunity. *Reviews of*
596 *Infectious Diseases*. **5 Suppl 5**, S979-984 (1983).

597 28 Vasil, M. L., Liu, P. V. & Iglewski, B. H. Temperature-dependent inactivating factor of
598 *Pseudomonas aeruginosa* exotoxin A. *Infection and Immunity*. **13**(5), 1467-1472 (1976).

599 29 Horii, T., Muramatsu, H., Monji, A. & Miyagishima, D. Release of exotoxin A,
600 peptidoglycan and endotoxin after exposure of clinical *Pseudomonas aeruginosa*
601 isolates to carbapenems in vitro. *Chemotherapy*. **51**(6), 324-331 (2005).

602 30 Kirikae, T. *et al.* Biological characterization of endotoxins released from antibiotic-
603 treated *Pseudomonas aeruginosa* and *Escherichia coli*. *Antimicrobial Agents and*
604 *Chemotherapy*. **42**(5), 1015-1021 (1998).



605 31 Morlon-Guyot, J., Mere, J., Bonhoure, A. & Beaumelle, B. Processing of *Pseudomonas*
606 *aeruginosa* exotoxin A is dispensable for cell intoxication. *Infection and Immunity*. **77**(7),
607 3090-3099 (2009).



608 32 Kim, Y. H. *et al.* 3,3'-diindolylmethane attenuates colonic inflammation and
609 tumorigenesis in mice. *Inflammatory Bowel Diseases*. **15**(8), 1164-1173 (2009).

610 33 Kanmani, P. *et al.* Probiotics and its functionally valuable products-a review. *Critical*
611 *Reviews in Food Science and Nutrition*. **53**(6), 641-658 (2013).

612 34 Nguyen, M. T. & Gotz, F. Lipoproteins of Gram-Positive Bacteria: Key Players in the
613 Immune Response and Virulence. *Microbiology and Molecular Biology Reviews* **80**(3),
614 891-903 (2016).

615









Table 1: Recipes of culture growth media and buffers.

Normal NGM agar media – 500 ml for maintenance and testing the effect of different bacteria
1. Add 1.25 g of peptone, 1.5 g of NaCl, 8.5 g of agar, and 487.5 mL of distilled water into a glass bottle.
2. Autoclave for 15 min at 121 °C.
3. Cool down in a water bath for 30 min at 55 °C, and then add 0.5 mL of 1 M CaCl ₂ , 0.5 mL of 5 mg/mL cholesterol (dissolved in ethanol), 0.5 mL of 1 M MgSO ₄ , 12.5 mL of KPO ₄ .
4. Mix with magnetic stirring, and then aliquot into Petri dishes (90 × 15 mm dishes for the maintenance and the bacterial treatment; 60 × 15 mm dishes for the FITC-dextran feeding).
5. Store the NGM plates at 4 °C until use.

DYT media for the cultivation of <i>E. coli</i> OP50 – 500 ml
1. Add 3 g of NaCl, 6 g of yeast extract, 9.6 g of peptone, and 580 mL of distilled water into an Erlenmeyer flask.
2. Autoclave for 15 min at 121 °C.
3. Cool down and store at room temperature until use.

LB media for the cultivation of <i>P. aeruginosa</i> PAO1 – 500 mL
1. Add 12.5 g LB medium powder (or 5 g tryptone, 2.5 g yeast extract and 5 g sodium chloride) and 487.5 mL distilled water into an Erlenmeyer flask.
2. Autoclave for 15 min at 121 °C.
3. Cool down and store at room temperature until use.

BHI media for the cultivation of <i>E. faecalis</i> KCTC3206 – 500 mL
1. Add 26 g of BHI medium power (or 3.85 g of calf brains, 4.9 g of beef heart, 5 g of proteose peptone, 1 g of dextrose, 2.5 g of sodium chloride, and 1.25 g of disodium phosphate) and 474 mL of distilled water into an Erlenmeyer flask.
2. Autoclave for 15 min at 121 °C.
3. Cool down and store at room temperature until use.

S-buffer – 1000 ml
1. Add 5.85 g of NaCl, 6 g of KH ₂ PO ₄ , 1 g of K ₂ HPO ₄ , and 987 mL of distilled water into a glass bottle.
2. Adjust the pH of the solution to 6.0.
3. Autoclave for 15 min at 121 °C.
4. Cool down and store at room temperature until use.

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Measuring the Effects of Bacteria and Chemicals on the Intestinal Permeability of *Caenorhabditis elegans*

Author(s):

Tram Anh Ngoc Le, Baskar Selvaraj, Jae Wook Lee, Kyungsu Kang*

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☒ Standard Access

☐ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:

Kyungsu Kang

Department:

Natural Product Informatics Research Center

Institution:

Korea Institute of Science and Technology

Title:

Senior Research Scientist

Signature:

Kyungsu Kang

Date:

12-June-2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Journal of Visualized Experiments
Editorial Office

Re: Manuscript ID, JoVE60419R1

August 27, 2019

Dear Dr. Bing Wu

Thank you for the review of our manuscript titled “**Measuring the Effects of Bacteria and Chemicals on the Intestinal Permeability of *Caenorhabditis elegans***”, which we recently submitted for publication in *JoVE*. We are grateful for the careful review, which has been helpful in producing a revised manuscript.

We have revised the manuscript to address the concerns of the editors, and we resubmit in the hope that it will now be acceptable for publication. A detailed response to each comment is appended. All the changes are shown in red in the revised manuscript.

We appreciate your comments and look forward to publication of the manuscript.

Sincerely,

Kyungsu Kang Ph.D.

Senior Research Scientist, Korea Institute of Science and Technology

Associate Professor, Korea University of Science and Technology

Editorial comments:

The manuscript has been modified and the updated manuscript, **60419_R1.docx**, is attached and located in your Editorial Manager account. **Please use the updated version to make your revisions.**

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

⇒ We proofread again the entire manuscript.

2. The highlighted protocol steps are over the 2.75 page limit (including headings and spacing). Please highlight fewer steps for filming.

⇒ We revised.

3. Please do not use more than 1 note for each step. Please avoid long notes (more than 4 lines).

⇒ We revised.

4. Please remove the embedded figure(s) from the manuscript. All figures should be uploaded separately to your Editorial Manager account.

⇒ We revised.



Editing Certificate

This document certifies that the manuscript

Measuring the Effects of Bacteria and Chemicals on the Intestinal Permeability of *Caenorhabditis elegans*

prepared by the authors

Tram Anh Ngoc Le, Baskar Selvaraj, Jae Wook Lee, Kyungsu Kang

was edited for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English speaking editors at AJE.

This certificate was issued on **August 23, 2019** and may be verified on the [AJE website](#) using the verification code **1B74-AAF0-9983-0989-69FP**.



Neither the research content nor the authors' intentions were altered in any way during the editing process. Documents receiving this certification should be English-ready for publication; however, the author has the ability to accept or reject our suggestions and changes. To verify the final AJE edited version, please visit our verification page at [aje.com/certificate](#). If you have any questions or concerns about this edited document, please contact AJE at support@aje.com.

AJE provides a range of editing, translation, and manuscript services for researchers and publishers around the world.

For more information about our company, services, and partner discounts, please visit [aje.com](#).